CJC-1295 + Ipamorelin: GH Secretagogue Synergy and the Dosing Rationale

CJC-1295 + Ipamorelin: GH Secretagogue Synergy and the Dosing Rationale

CJC-1295 and Ipamorelin target growth hormone (GH) secretion through complementary receptor pathways, which is why they’re typically studied in combination rather than isolation. Understanding the synergy requires understanding each mechanism separately first.

CJC-1295: GHRH Analog

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), the hypothalamic peptide that stimulates pituitary somatotrophs to produce and release GH. The standard research form is CJC-1295 with DAC (Drug Affinity Complex) — a lysine modification that allows the peptide to bind albumin, dramatically extending half-life from minutes (native GHRH) to approximately 8 days.

The extended half-life creates a sustained elevation in GH baseline rather than the sharp pulses produced by native GHRH. This matters clinically: continuous GH receptor stimulation without pulsatility can downregulate receptor sensitivity over time. This is one reason the CJC-1295/Ipamorelin stack became the standard approach rather than CJC-1295 alone.

Ipamorelin: Selective GH Secretagogue

Ipamorelin is a pentapeptide ghrelin receptor agonist (GHS-R1a) — a distinct receptor from the GHRH receptor, operating through a separate signaling pathway (primarily via IP3/DAG rather than cAMP). Ipamorelin stimulates GH release in a pulsatile pattern that more closely mimics physiological secretion.

The selective adjective is important: Ipamorelin has high selectivity for GH release with minimal effect on cortisol, prolactin, or ACTH — a cleaner profile compared to earlier GH secretagogues like GHRP-2 or GHRP-6, which produced significant cortisol and prolactin elevation. This selectivity makes it the preferred GHS-R agonist for stacking.

Synergy Mechanism

The combination works through receptor pathway amplification. GHRH (via CJC-1295) acts on the GHRH receptor and elevates somatotroph cAMP, priming pituitary cells for GH release. Ipamorelin acts on GHS-R1a through a different intracellular cascade, providing an additive signal. The combined stimulation produces GH pulse amplitudes significantly greater than either agent alone — documented in multiple animal and human studies.

CJC-1295 (with DAC) published Phase II data (Teichman et al., 2006, Journal of Clinical Endocrinology & Metabolism) demonstrating dose-dependent mean GH increases of 2–10 fold over baseline in healthy adults, with corresponding IGF-1 elevations of 30–70%. Safety was acceptable at doses studied. Ipamorelin’s human data is primarily from pharmaceutical development programs for GI motility (Helsinn, Rhythm Pharmaceuticals), where GH effects were secondary endpoints.

Dosing Rationale

The standard research approach uses CJC-1295 with DAC at 1–2 mg/week (exploiting the 8-day half-life to avoid daily injections) combined with Ipamorelin at 100–300 mcg per injection 2–3 times daily. The Ipamorelin pulses restore pulsatility to what would otherwise be a flat CJC-1295 GH elevation. Timing before sleep or fasting aligns with endogenous GH secretion patterns.

Bottom Line

The CJC-1295/Ipamorelin stack has genuine mechanistic synergy — GHRH axis and ghrelin receptor axis stimulated simultaneously, producing amplified pulsatile GH release with a profile cleaner than exogenous hGH administration. Phase II human data exists for CJC-1295. Ipamorelin’s selectivity for GH over cortisol/prolactin is pharmacologically documented. This is one of the better-characterized peptide stacks with a coherent rationale behind the combination.